Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in metastatic endometrial cancer resistant to first-line chemotherapy
2007-003002-10Phase 2Active
- Sponsor
- Arcagy-Gineco
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in endometrial cancer (EC) and Neoplasm, sponsored by Arcagy-Gineco. Primary endpoints: Non-progression rate at 3 months, Tumoral response at 3 months and 1 more. Started Sep 2007; status: active.
02
Drugs
everolimus
03
Conditions
endometrial cancer (EC)Neoplasm
Beyond the preview
Go deeper on 2007-003002-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003002-10.